TRAVASOL 5.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER

Clinical safety rating: caution

Comprehensive clinical and safety monograph for TRAVASOL 5.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER (TRAVASOL 5.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER).

How it works

Travasol 5.5% with electrolytes provides a source of amino acids and electrolytes for parenteral nutrition, supporting protein synthesis and maintaining metabolic balance.

What the body does with it

Metabolism	Amino acids are metabolized via deamination, transamination, and urea cycle in the liver and peripheral tissues.
Excretion	Primarily renal; 90-100% eliminated as free amino acids, electrolytes, and water. Metabolized nitrogen is excreted as urea. Biliary/fecal: negligible (<2%).
Half-life	Not applicable; components are endogenous and rapidly cleared. Amino acids have short half-lives (e.g., alanine ~15 min; leucine ~30 min) and are continuously metabolized. Terminal elimination of water and electrolytes follows body fluid kinetics.
Protein binding	Negligible (<10%) for amino acids and electrolytes; amino acids are unbound in plasma; electrolytes are ionized and free.
Volume of Distribution	Not defined as a single value; amino acids distribute into total body water (Vd 0.5-0.6 L/kg); electrolytes distribute into extracellular (Na, Cl) or total body water (K, Mg).
Bioavailability	Not applicable; intravenous administration provides 100% bioavailability.
Onset of Action	Intravenous: immediate (within seconds to minutes) for correction of fluid and electrolyte imbalances; metabolic effects begin with infusion.
Duration of Action	Intravenous: duration limited to infusion interval (e.g., 8-12 hours per bag). Continuous infusion required for sustained nutritional support; effects resolve shortly after discontinuation.

Classification & Brands

Dosing & administration

Intravenous: 500 mL to 2 L per day, infused at a rate of 20-40 mL/kg/day (0.5-1.5 g amino acids/kg/day) based on metabolic needs and tolerance.

Dosage form	INJECTABLE
Renal impairment	GFR <50 mL/min: Use with caution, adjust protein intake to 0.6-1.0 g/kg/day; monitor electrolytes and nitrogen balance. GFR <20 mL/min: Avoid or reduce dose, may require specialized renal formulations.
Liver impairment	Child-Pugh Class B or C: Reduce dose to 0.5-0.8 g amino acids/kg/day; avoid in severe hepatic encephalopathy.
Pediatric use	Neonates and infants: 0.5-2.0 g amino acids/kg/day (20-40 mL/kg/day of 5.5% solution); titrate based on growth and metabolic status.
Geriatric use	No specific dose adjustments but may require lower infusion rates due to decreased renal and hepatic function; monitor fluid and electrolyte balance closely.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for TRAVASOL 5.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER (TRAVASOL 5.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER).

Breastfeeding	Excreted into breast milk? Not specifically studied; components of parenteral nutrition are physiological and likely safe when used appropriately. No M/P ratio available. Use with caution in nursing mothers, balancing need for maternal nutrition.
Teratogenic Risk	No evidence of teratogenicity in animal studies; safety in human pregnancy not established. However, TRAVASOL 5.5% with electrolytes is an amino acid solution used for parenteral nutrition, essential for maternal and fetal nutrition in cases of malnutrition. Risk of fetal harm from deficiency outweighs potential risks. No known teratogenic effects from standard use.

Warnings & precautions

■ FDA Black Box Warning

None

Side Effect Profile

Serious Effects

Absolute Contraindications

["Severe metabolic acidosis","Hepatic coma","Uremia without dialysis support","Hypersensitivity to any component"]

Clinical Precautions

Precautions

["Risk of infection from catheter-related complications","Fluid and electrolyte imbalances","Hyperglycemia or hypoglycemia","Hepatic or renal impairment","Aluminum toxicity (prolonged use)"]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

TRAVASOL 5.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER

Clinical safety rating: caution

Comprehensive clinical and safety monograph for TRAVASOL 5.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER (TRAVASOL 5.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER).

How it works

Travasol 5.5% with electrolytes provides a source of amino acids and electrolytes for parenteral nutrition, supporting protein synthesis and maintaining metabolic balance.

What the body does with it

Metabolism	Amino acids are metabolized via deamination, transamination, and urea cycle in the liver and peripheral tissues.
Excretion	Primarily renal; 90-100% eliminated as free amino acids, electrolytes, and water. Metabolized nitrogen is excreted as urea. Biliary/fecal: negligible (<2%).
Half-life	Not applicable; components are endogenous and rapidly cleared. Amino acids have short half-lives (e.g., alanine ~15 min; leucine ~30 min) and are continuously metabolized. Terminal elimination of water and electrolytes follows body fluid kinetics.
Protein binding	Negligible (<10%) for amino acids and electrolytes; amino acids are unbound in plasma; electrolytes are ionized and free.
Volume of Distribution	Not defined as a single value; amino acids distribute into total body water (Vd 0.5-0.6 L/kg); electrolytes distribute into extracellular (Na, Cl) or total body water (K, Mg).
Bioavailability	Not applicable; intravenous administration provides 100% bioavailability.
Onset of Action	Intravenous: immediate (within seconds to minutes) for correction of fluid and electrolyte imbalances; metabolic effects begin with infusion.
Duration of Action	Intravenous: duration limited to infusion interval (e.g., 8-12 hours per bag). Continuous infusion required for sustained nutritional support; effects resolve shortly after discontinuation.

Classification & Brands

Dosing & administration

Intravenous: 500 mL to 2 L per day, infused at a rate of 20-40 mL/kg/day (0.5-1.5 g amino acids/kg/day) based on metabolic needs and tolerance.

Dosage form	INJECTABLE
Renal impairment	GFR <50 mL/min: Use with caution, adjust protein intake to 0.6-1.0 g/kg/day; monitor electrolytes and nitrogen balance. GFR <20 mL/min: Avoid or reduce dose, may require specialized renal formulations.
Liver impairment	Child-Pugh Class B or C: Reduce dose to 0.5-0.8 g amino acids/kg/day; avoid in severe hepatic encephalopathy.
Pediatric use	Neonates and infants: 0.5-2.0 g amino acids/kg/day (20-40 mL/kg/day of 5.5% solution); titrate based on growth and metabolic status.
Geriatric use	No specific dose adjustments but may require lower infusion rates due to decreased renal and hepatic function; monitor fluid and electrolyte balance closely.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for TRAVASOL 5.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER (TRAVASOL 5.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER).

Breastfeeding	Excreted into breast milk? Not specifically studied; components of parenteral nutrition are physiological and likely safe when used appropriately. No M/P ratio available. Use with caution in nursing mothers, balancing need for maternal nutrition.
Teratogenic Risk	No evidence of teratogenicity in animal studies; safety in human pregnancy not established. However, TRAVASOL 5.5% with electrolytes is an amino acid solution used for parenteral nutrition, essential for maternal and fetal nutrition in cases of malnutrition. Risk of fetal harm from deficiency outweighs potential risks. No known teratogenic effects from standard use.

Warnings & precautions

■ FDA Black Box Warning

None

Side Effect Profile

Serious Effects

Absolute Contraindications

["Severe metabolic acidosis","Hepatic coma","Uremia without dialysis support","Hypersensitivity to any component"]

Clinical Precautions

Precautions

["Risk of infection from catheter-related complications","Fluid and electrolyte imbalances","Hyperglycemia or hypoglycemia","Hepatic or renal impairment","Aluminum toxicity (prolonged use)"]

Clinical Tips & Counseling

Drug interactions

Loading safety data…